Medicamen Organics Ltd. · NSE:MEDIORG
Medicamen Organics — Investor Presentation (June 2025)
24 slides from Medicamen Organics's investor presentation, Jun 4, 2025
Slide 1: Covering letter to NSE: Investor Presentation
June 4, 2025 To, National Stock Exchange of India Limited Listing & Compliance Department Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra Mumbai, Maharashtra, 400051, India Company Symbol : MEDIORG Company ISIN : INE0PE401018 Dear Sir / Madam, Subject: Investor Present
Slide 2: Medicamen Organics Ltd Investor Memorandum
MEDICAMEN ORGANICS LTD INVESTOR MEMORANDUM
Slide 3: Disclaimer
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Medicamen Organics Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, an
Slide 4: Content
content 01 About Us 02 Products 03 Business Model Table of 04 05 Growth Drivers Financials
Slide 5: About Us
We are engaged in developing, manufacturing and distribution of broad range of pharmaceutical dosage including generic dosage in form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders for government (including both state and central governments) and private insti
Slide 6: Products
PRODUCTS PRODUCT PRODUCT PORTFOLIO DEVELOPMENT Our product portfolio consists of We are regularly engaged in 84 products and comprises of research and development wide range of drugs like, Anti- and launching new Bacterial, Anti Diarrheal, Anti- products. This gives us an Fungal, Anti-Malarial, Anti
Slide 7: Products
PRODUCTS CAPSULES OINTMENT/EXTERNAL DRY POWDER We are manufacturing sachets like Various capsule formulation/ PREPARATION pre and probiotic in granular form. compositions are being We are producing antifungal/anti- Diclofenac Potassium and Sodium manufactured by us including but bacterial formulatio
Slide 8: Marquee Clients
EUROPA ; Healing FRANK ROSS _Biocare Pvt. Ltd. MART) GRSVETY —_— Pharma, LIFECARE LLP Lvealth BioPharma Pvt. Ltd. git KA Rott KILITCH DRUGS EMAMI a Anglo-French Drugs & - oN Industries Limited ‘ Ybr. Morepen” FRANK ROSS
Slide 9: Awards & Accreditation
AWARDS & ACCREDITATION Our Company received Pharmexcil Award in the Our Direct receiving Niryat Shree Award for Out Medicamen organics Ltd received Pharma category of “Fast Emerging Company” for the year Standing Export from Hon’ble Shri Pranab Ratna Awartd (For fastest growing company) of 2008-09 w
Slide 10: Growth Drivers
Scalable Business Model Our business model is customer centric and order driven, and requires optimum utilisation of our existing resources, assuring quality supply and achieving consequent economies of scale. GROWTH The business scale generation is basically due to development of new markets and pr
Slide 11: Growth Drivers: Wide Range of Products
GROWTH DRIVERS # Wide Range of Products Wide Range of Products # Customer Satisfaction We deal in Capsules, Tablets, Liquid Ointment, Gel, Syrups, Suspension and Dry powders. Our product portfolio comprises of wide range of drugs like Anti- Bacterial, Anti Diarrheal, Anti-Fungal, Anti-Malarial, Anti
Slide 12: Growth Drivers: Customer Satisfaction
GROWTH DRIVERS # Wide Range of Products Customer Satisfaction # Customer Satisfaction The business of our Company is customer oriented and always strives to maintain good relationship with the customers. Our Company’s marketing team approaches existing customers for their feedback # Increasing Manuf
Slide 13: Growth Drivers: Increasing Manufacturing Capacities
GROWTH DRIVERS # Wide Range of Products Increasing Manufacturing Capacities in target Markets # Customer Satisfaction Grande Etoile Pharmaceuticals Limited (GEPL) is a recently incorporated subsidiary of Medicamen Organics Limited (MOL), in which MOL holds a majority equity stake of 50.92%. GEPL is
Slide 14: Growth Drivers: Nepal Manufacturing Collaboration
GROWTH DRIVERS # Wide Range of Products Increasing Manufacturing Capacities in target Markets # Medicamen Organics Limited (MOL), through its subsidiary GEPL, has Customer Satisfaction entered into a strategic investment and manufacturing collaboration with Medi Hub Organic Ltd. (MHOL), a newly inco
Slide 15: Growth Drivers: Rwanda Expansion
GROWTH DRIVERS # Wide Range of Products Improve Global Presence # Customer Satisfaction RWANDA EXPANSION 1. Medicamen Organics Limited sarted a subsidiary in Rwanda, MOU # Increasing Manufacturing Capacities in Signed on 15t July, 2024. target Markets 2. Rwanda is a Safe, Fast growing, Lucrative mar
Slide 16: Growth Drivers: Mauritius Expansion
GROWTH DRIVERS # Wide Range of Products Improve Global Presence # Customer Satisfaction MAURITIUS EXPANSION # Increasing Manufacturing Capacities in 1. GEPL, a subsidiary of Medicamen Organics Limited plans to target Markets start a subsidiary in Mauritius, MOU expected in August. 2. Mauritius is a
Slide 17: Growth Drivers: New Product Segments - Cosmetics & Skin Care
GROWTH DRIVERS # Wide Range of Products New Product Segments- Cosmetics & Skin Care # Customer Satisfaction Medicamen Organics Limited has entered the beauty and personal care industry through its subsidiary, GEPL, launching its first product line in Q1 FY 2025–26 following a successful trial in Nep
Slide 18: Meet Our Team
Meet Our Team BAL KISHAN GUPTA ASHUTOSH GUPTA BIRJESH KUMAR CHAUBEY Bal Kishan Gupta, Indian National, aged Ashutosh Gupta, Indian National, aged Mr. Brijesh Kumar Chaubey, M. Pharm, 72 years, is the Promoter of our 44 years, is a Whole-time Director of our is a seasoned pharmaceutical Company. He i
Slide 19: Consolidated FY25 YoY Performance Highlights
CONSOLIDATED FY25 YOY PERFORMANCE HIGHLIGHTS Revenue (In Lakhs) EBITDA (In Lakhs) PAT (In Lakhs) 668.07 404.71 3,818.77 475.56 2,527.17 262.43 FY24 FY25 FY24 FY25 FY24 FY25 EBITDA Margin (%) PAT Margin (%) EPS (In Lakhs) 3.47 3.67 18.80% 10.38% 10.60% 17.45% FY24 FY25 FY24 FY25 FY24 FY25
Slide 20: Consolidated H2 FY25 YoY Performance Highlights
CONSOLIDATED H2 FY25 YOY PERFORMANCE HIGHLIGHTS Revenue (In Lakhs) EBITDA (In Lakhs) PAT (In Lakhs) 390.64 2,157.72 253.64 234.41 1,395.17 126.18 H2 FY24 H2 FY25 H2 FY24 H2 FY25 H2 FY24 H2 FY25 EBITDA Margin (%) PAT Margin (%) EPS (In Lakhs) 2.19 16.79% 18.06% 11.76% 9.04% 1.52 H2 FY24 H2 FY25 H2 FY
Slide 21: Consolidated Financials: Income Statement
` CONSOLIDATED Particulars H2 FY25 H2 FY24 YOY FY25 FY24 YOY Revenues 2,157.72 1,395.17 54.66% 3,818.77 2,527.17 51.11% FINANCIALS Other Income 5.21 1.20 9.50 1.79 Income Total Income 2,162.94 1,396.37 54.90% 3,828.27 2,528.96 51.38% Raw Materials 1,153.69 764.87 2,143.75 1,292.95 Statement Direct E
Slide 22: Consolidated Financials: Balance Sheet
CONSOLIDATED Balance Sheet FINANCIALS In Lakhs Equities & Liabilities FY25 FY24 Assets FY25 FY24 Equity 1,170.00 860.00 Non Current Assets Minority Interest 35.14 0.00 Reserves 1,767.92 665.94 Fixed Assets 1234.56 1049.56 Money Received agaist share warrants 75.00 0.00 Long-term Loans & Advances 0.0
Slide 23: Stock Data: Shareholding Pattern
Stock Data SHAREHOLDING PATTERN ₹ ₹ 40.27% 59.73% ₹ ₹ Promoter & Promoter Group Public As on 03/06/2025
Slide 24: Thank You
Thank You. Medicamen Organics Ltd www.medicamenorganics.com Company Investor Relations Advisors Medicamen Organics Limited EquiBridgex Advisors Pvt Ltd - Ms. Pooja Gandhi sale@mediorganics.in info@equibridgex.com www.medicamenorganics.com www.equibridgex.com
Medicamen Organics — Investor Presentation (June 2025) on 6ix